Blood Biomarker Predicts Heart Disease Risk in Atrial Fibrillation Patients

Researchers have discovered that a simple blood test measuring neurofilament light chain (sNfL) can powerfully predict cardiovascular risk in people with atrial fibrillation, potentially revolutionizing how doctors assess and manage this common heart rhythm disorder affecting millions worldwide.

The Swiss study followed 2,311 atrial fibrillation patients for 8 years across 14 medical centers. Scientists measured sNfL levels in blood samples and tracked major cardiovascular events including heart attacks, strokes, and deaths. Originally developed to detect brain injury, sNfL appears to reflect broader vascular damage throughout the body.

The results were striking: every doubling of sNfL levels increased major cardiovascular events by 35%, stroke risk by 31%, cardiovascular death by 36%, and overall mortality by 41%. Heart failure hospitalizations also increased by 25%. Notably, sNfL didn't predict heart attacks specifically, suggesting it may reflect different disease mechanisms than traditional risk factors.

For longevity-focused individuals, this research highlights the importance of comprehensive cardiovascular risk assessment beyond standard markers like cholesterol. Atrial fibrillation affects over 33 million people globally and significantly reduces lifespan through increased stroke and heart failure risk. Early identification of high-risk patients could enable more aggressive preventive interventions.

However, sNfL testing isn't yet clinically available, and the study only included patients who already had atrial fibrillation. Whether sNfL predicts cardiovascular risk in healthy individuals remains unknown. Additionally, researchers haven't determined if interventions can lower sNfL levels or improve outcomes in high-risk patients identified through this biomarker.